Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash from Operations: 2019-2023

Historic Cash from Operations for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2023 value amounting to -$31.6 million.

  • ADC Therapeutics' Cash from Operations rose 77.12% to -$31.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$118.7 million, marking a year-over-year increase of 14.19%. This contributed to the annual value of -$123.8 million for FY2024, which is 4.34% down from last year.
  • Latest data reveals that ADC Therapeutics reported Cash from Operations of -$31.6 million as of Q4 2023, which was up 13.74% from -$36.7 million recorded in Q3 2023.
  • In the past 5 years, ADC Therapeutics' Cash from Operations registered a high of $2,195 during Q3 2022, and its lowest value of -$233.2 million during Q4 2021.
  • In the last 3 years, ADC Therapeutics' Cash from Operations had a median value of -$7.7 million in 2021 and averaged -$40.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first spiked by 103.75% in 2022, then crashed by 1,670,851.71% in 2023.
  • ADC Therapeutics' Cash from Operations (Quarterly) stood at -$122.3 million in 2019, then reached -$32.5 million in 2020, then spiked by 99.83% to -$233.2 million in 2021, then spiked by 40.73% to -$138.2 million in 2022, then surged by 77.12% to -$31.6 million in 2023.
  • Its Cash from Operations stands at -$31.6 million for Q4 2023, versus -$36.7 million for Q3 2023 and -$35.0 million for Q2 2023.